The sixth and last Multi-Stakeholder meeting organized by SIOP Europe took place on 28–29 April in Heidelberg and online. The meeting focused on Chronic Kidney Disease (CKD), a progressive condition that leads to end-stage kidney disease during childhood or at young adult age, with a large burden of comorbidities and major impact on life expectancy and quality of life. A MSM as a basis for a discussion of the framework to facilitate drug development for children with CKD between all stakeholders including FDA and EMA was considered highly beneficial. The meeting took place directly before the ESCAPE meeting in Heidelberg.
Over 120 people registered, including over 70 academics, researchers and clinicians, 20 patients and their advocates, 10 regulatory members (EMA, FDA and PDCO), and 20 members of the industry.
